This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
Print Document
View Excel Document
Cover
Document And Entity Information
Financial Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Earnings
Consolidated Statements of Equity
Consolidated Statements of Cash Flows
Notes to Financial Statements
Nature of Operations
Summary of Significant Accounting Policies
Acquisitions and Other Transactions
Balance Sheet Components
Equity Method Investments
Goodwill and Other Intangible Assets
Financial Instruments and Risk Management
Debt
Comprehensive Earnings
Income Taxes
Share-Based Incentive Plan
Employee Benefit Plans
Segment Information
Commitments
Subsidiary Guarantors
Contingencies
Subsequent Events
Other
Supplementary Financial Information
Valuation and Qualifying Accounts
Accounting Policies
Summary of Significant Accounting Policies (Policies)
Financial Instruments and Risk Management Financial Instruments and Risk Management (Policies)
Contingencies (Policies)
Notes Tables
Summary of Significant Accounting Policies (Tables)
Acquisitions and Other Transactions (Tables)
Balance Sheet Components (Tables)
Equity Method Investments (Tables)
Goodwill and Other Intangible Assets (Tables)
Financial Instruments and Risk Management (Tables)
Debt (Tables)
Comprehensive Earnings (Tables)
Income Taxes (Tables)
Share-Based Incentive Plan (Tables)
Employee Benefit Plans (Tables)
Segment Information (Tables)
Commitments (Tables)
Subsidiary Guarantors (Tables)
Supplementary Financial Information (Tables)
Valuation and Qualifying Accounts Valuation and Qualifying Accounts (Tables)
Notes Details
Nature of Operations (Narrative) (Details)
Summary of Significant Accounting Policies (Narrative) (Details)
Summary of Significant Accounting Policies (Major Customers) (Details)
Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details)
Acquisitions and Other Transactions (EPD Business) (Narrative) (Details)
Acquisitions and Other Transactions (EPD Business Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (EPD Business Pro Forma Financial Information) (Details)
Acquisitions and Other Transactions (Jai Pharma Limited) (Narrative) (Details)
Acquisitions and Other Transactions (Jai Pharma Limited Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (Agila Specialties) (Narrative) (Details)
Acquisitions and Other Transactions (Agila Specialties Schedule of Purchase Price Allocation) (Details)
Acquisitions and Other Transactions (Agila Specialties Pro Forma Financial Information) (Details)
Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details)
Balance Sheet Components (Narrative) (Details)
Balance Sheet Components (Inventories) (Details)
Balance Sheet Components (Property, Plant and Equipment) (Details)
Balance Sheet Components (Other Current Liabilities) (Details)
Equity Method Investments (Narrative) (Details)
Equity Method Investments (Balance Sheet) (Details)
Equity Method Investments (Income Statement) (Details)
Goodwill and Other Intangible Assets (Narrative) (Details)
Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details)
Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details)
Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details)
Financial Instruments and Risk Management (Narrative) (Details)
Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)
Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details)
Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details)
Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details)
Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details)
Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details)
Debt (Receivables Facility) (Narrative) (Details)
Debt (Summary of Long-term Debt) (Details)
Debt (Revolving Credit Agreement) (Narrative) (Details)
Debt (2015 Term Loans) (Narrative) (Details)
Debt (2014 Term Loans) (Narrative) (Details)
Debt (Cash Convertible Notes) (Narrative) (Details)
Debt (Summary of Cash Convertible Notes) (Details)
Debt (Senior Notes) (Narrative) (Details)
Debt (Bridge Credit Agreement) (Narrative) (Details)
Debt (Fair Value) (Narrative) (Details)
Debt (Minimum Repayments on Outstanding Borrowings) (Details)
Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details)
Comprehensive Earnings (Components of Other Comprehensive Loss) (Details)
Income Taxes (Narrative) (Details)
Income Taxes (Schedule of Components of Income Tax Provision) (Details)
Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details)
Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)
Income Taxes (Schedule of Unrecognized Tax Benefits) (Details)
Share-Based Incentive Plan (Narrative) (Details)
Share-Based Incentive Plan (Stock Awards) (Details)
Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details)
Share-Based Incentive Plan (Valuation Assumptions) (Details)
Employee Benefit Plans Employee Benefit Plans (Narrative) (Details)
Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details)
Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details)
Employee Benefit Plans (Net Periodic Benefit Costs) (Details)
Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details)
Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details)
Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details)
Employee Benefit Plans (Fair Values of Plan Assets) (Details)
Employee Benefit Plans (Weighted Average Assumptions) (Details)
Employee Benefit Plans (Effect of One Percentage Point Increase or Decrease in Health Care Cost Trend Rates) (Details)
Employee Benefit Plans (Estimated Future Benefit Payments) (Details)
Segment Information (Narrative) (Details)
Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details)
Segment Information (Net Third Party Sales Classified Based on Therapeutic Product Categories) (Details)
Segment Information (Net Third Party Sales Classified Based on Geographic Location of Customers) (Details)
Commitments (Narrative) (Details)
Commitments (Schedule of Operating Leases) (Details)
Subsidiary Guarantors Condensed Consolidating Balance Sheet (Details)
Subsidiary Guarantors Condensed Consolidating Statement of Operations (Details)
Subsidiary Guarantors Condensed Statement of Comprehensive Earnings (Details)
Subsidiary Guarantors Condensed Consolidating Statement of Cash Flows (Details)
Contingencies (Lorazepam and Clorazepate) (Narrative) (Details)
Contingencies (Pricing and Medicaid Litigation) (Narrative) (Details)
Contingencies (Modafinil Antitrust Litigation and FTC Inquiry) (Narrative) (Details)
Contingencies (Pioglitazone) (Narrative) (Details)
Contingencies (Shareholder Class Action) (Narrative) (Details)
Contingencies (Perrigo Litigation) (Narrative) (Details)
Contingencies (European Commission Proceedings) (Narrative) (Details)
Contingencies (U.K. Competition and Markets Authority) (Narrative) (Details)
Contingencies (Product Liability) (Narrative) (Details)
Contingencies (Intellectual Property) (Narrative) (Details)
Contingencies (Other Litigation) (Narrative) (Details)
Subsequent Events (Narrative) (Details)
Supplementary Financial Information (Quarterly Financial Data ) (Details)
Valuation and Qualifying Accounts (Details)
All Reports
Rendering Log